CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660. The company also... Read More

Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously treated with topoisomerase-1 inhibitor (topo-1) ADCs; confirmed responses observed across all enrolled tumor types First expansion cohort initiated in patients with TNBC previously treated with at least one topo-1... Read More

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting... Read More

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday,... Read More

Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage... Read More

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August... Read More

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit... Read More

Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan... Read More

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a... Read More

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9,... Read More

CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a... Read More

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056 restarting; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026 Conference call... Read More

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference... Read More

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on... Read More

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024... Read More

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056, Immunosynthen HER2 ADC, restarting; plan to advance dose escalation in 2024 Expect capital resources will support current operating plan commitments into 2026 Company to webcast... Read More

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a... Read More

Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:... Read More

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday,... Read More

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Phase 1 clinical trial of XMT-2056.... Read More

Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of Directors Martin Huber, M.D., current member of the Board of Directors, to be named President and CEO Brian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage... Read More

Organization fully focused on product candidates and collaborations based on next-generation ADC platforms Capital resources expected to support current operating plan commitments into 2026 CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting... Read More

CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on August 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock... Read More

UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in... Read More

CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on July 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock... Read More

CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and... Read More

CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on June 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock... Read More

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 4 th Annual Oncology Innovation Summit... Read More

Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023 Advanced enrollment in Phase 3 UP-NEXT clinical trial of UpRi and Phase 1 clinical trial of XMT-1660 Plan to report topline data from UPLIFT registrational trial in mid-2023; potential Biologics License Application (BLA) submission anticipated around the end of 2023 Capital... Read More

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock... Read More

CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20... Read More

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9,... Read More

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the acceptance of multiple abstracts for poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual... Read More

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock... Read More

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Phase 1 trial of XMT-2056 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). This action... Read More

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana’s capital is currently held in a checking account at Silicon... Read More

CAMBRIDGE, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on March 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of... Read More

Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatin Initiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate, XMT-2056 Entered new research collaboration and commercial license agreement with Merck KGaA, Darmstadt, Germany Anticipate topline data from UPLIFT registrational trial in mid-2023; potential Biologics License Application (BLA)... Read More

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on... Read More

CAMBRIDGE, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on February 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of... Read More

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: Guggenheim Oncology Conference Format: Fireside... Read More

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in... Read More

CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate.... Read More

CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on January 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock... Read More

Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024 Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancer Advance XMT-1660 and XMT-2056 Phase 1 trials Continue pursuing collaborations to maximize platform and pipeline potential Capital resources expected to support operating... Read More

Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive $30 million upfront payment, up to $800 million in development, regulatory and commercial milestones, and tiered royalties up to the low double-digit percentages on net sales Mersana’s third significant collaboration agreement in 2022 reflects its increasing role... Read More

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the European Commission (EC) has designated upifitamab rilsodotin (UpRi) as an orphan medicinal product for the treatment of... Read More